Dirk Grimm - Publications

Heidelberg University Hospital 
RNAi, gene therapy, AAV, iPS cells, genome engineering

74 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Eichhoff AM, Börner K, Albrecht B, Schäfer W, Baum N, Haag F, Körbelin J, Trepel M, Braren I, Grimm D, Adriouch S, Koch-Nolte F. Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors. Molecular Therapy. Methods & Clinical Development. 15: 211-220. PMID 31687421 DOI: 10.1016/j.omtm.2019.09.003  0.44
2019 Hoffmann MD, Aschenbrenner S, Grosse S, Rapti K, Domenger C, Fakhiri J, Mastel M, Börner K, Eils R, Grimm D, Niopek D. Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins. Nucleic Acids Research. PMID 30982889 DOI: 10.1093/nar/gkz271  0.44
2019 Fanucchi S, Fok ET, Dalla E, Shibayama Y, Börner K, Chang EY, Stoychev S, Imakaev M, Grimm D, Wang KC, Li G, Sung WK, Mhlanga MM. Publisher Correction: Immune genes are primed for robust transcription by proximal long noncoding RNAs located in nuclear compartments. Nature Genetics. PMID 30647470 DOI: 10.1038/s41588-018-0341-3  0.44
2018 Fanucchi S, Fok ET, Dalla E, Shibayama Y, Börner K, Chang EY, Stoychev S, Imakaev M, Grimm D, Wang KC, Li G, Sung WK, Mhlanga MM. Immune genes are primed for robust transcription by proximal long noncoding RNAs located in nuclear compartments. Nature Genetics. PMID 30531872 DOI: 10.1038/s41588-018-0298-2  0.44
2018 Herrmann AK, Bender C, Kienle E, Grosse S, El Andari J, Botta J, Schürmann N, Wiedtke E, Niopek D, Grimm D. A robust and all-inclusive pipeline for shuffling of Adeno-associated viruses (AAV). Acs Synthetic Biology. PMID 30513195 DOI: 10.1021/acssynbio.8b00373  0.44
2018 Bubeck F, Hoffmann MD, Harteveld Z, Aschenbrenner S, Bietz A, Waldhauer MC, Börner K, Fakhiri J, Schmelas C, Dietz L, Grimm D, Correia BE, Eils R, Niopek D. Engineered anti-CRISPR proteins for optogenetic control of CRISPR-Cas9. Nature Methods. 15: 924-927. PMID 30377362 DOI: 10.1038/s41592-018-0178-9  0.44
2018 Herrmann AK, Grosse S, Börner K, Krämer C, Wiedtke E, Gunkel M, Grimm D. Impact of the assembly-activating protein (AAP) on molecular evolution of synthetic Adeno-associated virus (AAV) capsids. Human Gene Therapy. PMID 29978729 DOI: 10.1089/hum.2018.085  0.44
2018 Cordas Dos Santos DM, Eilers J, Sosa Vizcaino A, Orlova E, Zimmermann M, Stanulla M, Schrappe M, Börner K, Grimm D, Muckenthaler MU, Kulozik AE, Kunz JB. MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB. Bmc Cancer. 18: 663. PMID 29914415 DOI: 10.1186/s12885-018-4525-0  0.44
2017 Kunze C, Börner K, Kienle E, Orschmann T, Rusha E, Schneider M, Radivojkov-Blagojevic M, Drukker M, Desbordes S, Grimm D, Brack-Werner R. Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia. PMID 29119608 DOI: 10.1002/glia.23254  0.44
2017 Große S, Penaud-Budloo M, Herrmann AK, Börner K, Fakhiri J, Laketa V, Krämer C, Wiedtke E, Gunkel M, Ménard L, Ayuso E, Grimm D. Relevance of assembly-activating protein for Adeno-associated virus vector production and capsid protein stability in mammalian and insect cells. Journal of Virology. PMID 28768875 DOI: 10.1128/JVI.01198-17  0.44
2016 Rezvani M, Español-Suñer R, Malato Y, Dumont L, Grimm AA, Kienle E, Bindman JG, Wiedtke E, Hsu BY, Naqvi SJ, Schwabe RF, Corvera CU, Grimm D, Willenbring H. In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis. Cell Stem Cell. 18: 809-816. PMID 27257763 DOI: 10.1016/j.stem.2016.05.005  0.4
2016 Hentzschel F, Herrmann AK, Mueller AK, Grimm D. Plasmodium meets AAV - the (un)likely marriage of parasitology and virology, and how to make the match. Febs Letters. PMID 27117587 DOI: 10.1002/1873-3468.12187  1
2016 Liesche C, Venkatraman L, Aschenbrenner S, Grosse S, Grimm D, Eils R, Beaudouin J. Death receptor-based enrichment of Cas9-expressing cells Bmc Biotechnology. 16. DOI: 10.1186/s12896-016-0250-4  1
2015 Singer M, Marshall J, Heiss K, Mair GR, Grimm D, Mueller AK, Frischknecht F. Zinc finger nuclease-based double-strand breaks attenuate malaria parasites and reveal rare microhomology-mediated end joining. Genome Biology. 16: 249. PMID 26573820 DOI: 10.1186/s13059-015-0811-1  1
2015 Grimm D, Zolotukhin S. E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal-Tailored Acceleration of AAV Evolution. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26388463 DOI: 10.1038/mt.2015.173  1
2015 Mockenhaupt S, Grosse S, Rupp D, Bartenschlager R, Grimm D. Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys. Proceedings of the National Academy of Sciences of the United States of America. 112: E4007-16. PMID 26170322 DOI: 10.1073/pnas.1510476112  1
2015 Mueller S, Huard J, Waldow K, Huang X, D'Alessandro LA, Bohl S, Börner K, Grimm D, Klamt S, Klingmüller U, Schilling M. T160‐phosphorylated CDK2 defines threshold for HGF dependent proliferation in primary hepatocytes. Molecular Systems Biology. 11: 795. PMID 26148348  0.44
2015 Schmidt F, Grimm D. CRISPR genome engineering and viral gene delivery: a case of mutual attraction. Biotechnology Journal. 10: 258-72. PMID 25663455 DOI: 10.1002/biot.201400529  1
2015 Mueller S, Huard J, Waldow K, Huang X, D'Alessandro LA, Bohl S, Börner K, Grimm D, Klamt S, Klingmüller U, Schilling M. T160-phosphorylated CDK2 defines threshold for HGF-dependent proliferation in primary hepatocytes Molecular Systems Biology. 11. DOI: 10.15252/msb.20156032  1
2014 Carnero E, Barriocanal M, Segura V, Guruceaga E, Prior C, Börner K, Grimm D, Fortes P. Type I Interferon Regulates the Expression of Long Non-Coding RNAs. Frontiers in Immunology. 5: 548. PMID 25414701 DOI: 10.3389/fimmu.2014.00548  1
2014 Hentzschel F, Hammerschmidt-Kamper C, Börner K, Heiss K, Knapp B, Sattler JM, Kaderali L, Castoldi M, Bindman JG, Malato Y, Willenbring H, Mueller AK, Grimm D. AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically attenuated malarial parasites. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 2130-41. PMID 25189739 DOI: 10.1038/mt.2014.172  1
2014 Senís E, Fatouros C, Große S, Wiedtke E, Niopek D, Mueller AK, Börner K, Grimm D. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnology Journal. 9: 1402-12. PMID 25186301 DOI: 10.1002/biot.201400046  1
2014 Hörner M, Kaufmann B, Cotugno G, Wiedtke E, Büning H, Grimm D, Weber W. A chemical switch for controlling viral infectivity. Chemical Communications (Cambridge, England). 50: 10319-22. PMID 25058661 DOI: 10.1039/c4cc03292f  1
2013 Börner K, Niopek D, Cotugno G, Kaldenbach M, Pankert T, Willemsen J, Zhang X, Schürmann N, Mockenhaupt S, Serva A, Hiet MS, Wiedtke E, Castoldi M, Starkuviene V, Erfle H, ... ... Grimm D, et al. Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. Nucleic Acids Research. 41: e199. PMID 24049077 DOI: 10.1093/nar/gkt836  1
2013 Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Schürmann N, et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation. 128: 1420-32. PMID 23956210 DOI: 10.1161/CIRCULATIONAHA.112.001357  1
2013 Schürmann N, Trabuco LG, Bender C, Russell RB, Grimm D. Molecular dissection of human Argonaute proteins by DNA shuffling. Nature Structural & Molecular Biology. 20: 818-26. PMID 23748378 DOI: 10.1038/nsmb.2607  1
2012 Grimm D, Dalmay T, van Rij RP. Everybody wins! Poland hosts thrilling competitions of viruses, RNAi and football teams. Embo Reports. 13: 874-6. PMID 22986551 DOI: 10.1038/embor.2012.136  1
2012 Grimm D. All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1661-3. PMID 22945230 DOI: 10.1038/mt.2012.173  1
2012 Kienle E, Senís E, Börner K, Niopek D, Wiedtke E, Grosse S, Grimm D. Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling. Journal of Visualized Experiments : Jove. PMID 22491297 DOI: 10.3791/3819  1
2012 Valdmanis PN, Gu S, Schüermann N, Sethupathy P, Grimm D, Kay MA. Expression determinants of mammalian argonaute proteins in mediating gene silencing. Nucleic Acids Research. 40: 3704-13. PMID 22210886 DOI: 10.1093/nar/gkr1274  1
2011 Malato Y, Naqvi S, Schürmann N, Ng R, Wang B, Zape J, Kay MA, Grimm D, Willenbring H. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. The Journal of Clinical Investigation. 121: 4850-60. PMID 22105172 DOI: 10.1172/JCI59261  1
2011 Grimm D. The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression. Silence. 2: 8. PMID 22029761 DOI: 10.1186/1758-907X-2-8  1
2011 Niopek D, Berrens R, Mockenhaupt S, Lewis MD, Mueller AK, Grimm D. To go, or not to go, that is the question - six personal reflections on how geographic mobility may affect your career and life. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 33: 728-31. PMID 21858845 DOI: 10.1002/bies.201100083  1
2011 Mockenhaupt S, Schürmann N, Grimm D. When cellular networks run out of control: global dysregulation of the RNAi machinery in human pathology and therapy. Progress in Molecular Biology and Translational Science. 102: 165-242. PMID 21846572 DOI: 10.1016/B978-0-12-415795-8.00006-4  1
2011 Gu S, Jin L, Zhang F, Huang Y, Grimm D, Rossi JJ, Kay MA. Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes. Proceedings of the National Academy of Sciences of the United States of America. 108: 9208-13. PMID 21576459 DOI: 10.1073/pnas.1018023108  1
2011 Mockenhaupt S, Grimm D. Vectorology: Adeno-associated viruses for efficient gene targeting in human cells | Vektorologie: Adeno-assoziierte viren für effizientes gene targeting in humanen zellen Biospektrum. 17: 533-536. DOI: 10.1007/sl2268-011-0085-4  1
2010 Grimm D, Wang L, Lee JS, Schürmann N, Gu S, Börner K, Storm TA, Kay MA. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. The Journal of Clinical Investigation. 120: 3106-19. PMID 20697157 DOI: 10.1172/JCI43565  1
2010 Parameswaran P, Sklan E, Wilkins C, Burgon T, Samuel MA, Lu R, Ansel KM, Heissmeyer V, Einav S, Jackson W, Doukas T, Paranjape S, Polacek C, dos Santos FB, Jalili R, ... ... Grimm D, et al. Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. Plos Pathogens. 6: e1000764. PMID 20169186 DOI: 10.1371/journal.ppat.1000764  1
2010 Beer S, Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh H, Börner K, Storm TA, Davis CR, Kay MA, Felsher DW, Grimm D. Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 161-70. PMID 19844192 DOI: 10.1038/mt.2009.222  1
2010 Börner K, Grimm D. Use of small RNAs for therapeutic gene silencing: Risk versus benefit Drug Discovery Today: Technologies. 7: e51-e57. DOI: 10.1016/j.ddtec.2010.07.003  1
2009 Grimm D. Small silencing RNAs: state-of-the-art. Advanced Drug Delivery Reviews. 61: 672-703. PMID 19427885 DOI: 10.1016/j.addr.2009.05.002  1
2009 Grimm D. New concepts for siRNA design: The beauty of asymmetry: Asymmetry in siRNA design Gene Therapy. 16: 827-829. PMID 19404320 DOI: 10.1038/gt.2009.45  1
2008 Giering JC, Grimm D, Storm TA, Kay MA. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1630-6. PMID 18665161 DOI: 10.1038/mt.2008.144  1
2008 Doege H, Grimm D, Falcon A, Tsang B, Storm TA, Xu H, Ortegon AM, Kazantzis M, Kay MA, Stahl A. Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. The Journal of Biological Chemistry. 283: 22186-92. PMID 18524776 DOI: 10.1074/jbc.M803510200  1
2008 Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, Kay MA. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. Journal of Virology. 82: 5887-911. PMID 18400866 DOI: 10.1128/JVI.00254-08  1
2008 Streetz KL, Doyonnas R, Grimm D, Jenkins DD, Fuess S, Perryman S, Lin J, Trautwein C, Shizuru J, Blau H, Sylvester KG, Kay MA. Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells. Hepatology (Baltimore, Md.). 47: 706-18. PMID 18220289 DOI: 10.1002/hep.22012  1
2007 Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? The Journal of Clinical Investigation. 117: 3633-41. PMID 18060021 DOI: 10.1172/JCI34129  1
2007 Grimm D, Kay MA. RNAi and gene therapy: a mutual attraction. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 473-81. PMID 18024667 DOI: 10.1182/asheducation-2007.1.473  1
2007 Paskowitz DM, Greenberg KP, Yasumura D, Grimm D, Yang H, Duncan JL, Kay MA, Lavail MM, Flannery JG, Vollrath D. Rapid and stable knockdown of an endogenous gene in retinal pigment epithelium. Human Gene Therapy. 18: 871-80. PMID 17892416 DOI: 10.1089/hum.2007.065  1
2007 Grimm D, Kay MA. Combinatorial RNAi: a winning strategy for the race against evolving targets? Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 878-88. PMID 17311009 DOI: 10.1038/sj.mt.6300116  1
2007 Akache B, Grimm D, Shen X, Fuess S, Yant SR, Glazer DS, Park J, Kay MA. A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 330-9. PMID 17235311 DOI: 10.1038/sj.mt.6300053  1
2006 Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. Journal of Virology. 80: 9831-6. PMID 16973587 DOI: 10.1128/JVI.00878-06  1
2006 Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 441: 537-41. PMID 16724069 DOI: 10.1038/nature04791  1
2006 Grimm D, Kay MA. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Therapy. 13: 563-75. PMID 16453009 DOI: 10.1038/sj.gt.3302727  1
2006 Müller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA, Kleinschmidt JA. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovascular Research. 70: 70-8. PMID 16448634 DOI: 10.1016/j.cardiores.2005.12.017  1
2006 Grimm D, Pandey K, Nakai H, Storm TA, Kay MA. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. Journal of Virology. 80: 426-39. PMID 16352567 DOI: 10.1128/JVI.80.1.426-439.2006  1
2005 Riu E, Grimm D, Huang Z, Kay MA. Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo. Human Gene Therapy. 16: 558-70. PMID 15916481 DOI: 10.1089/hum.2005.16.558  1
2005 Grimm D, Pandey K, Kay MA. Adeno-associated virus vectors for short hairpin RNA expression. Methods in Enzymology. 392: 381-405. PMID 15644194 DOI: 10.1016/S0076-6879(04)92023-X  1
2003 Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Current Gene Therapy. 3: 281-304. PMID 12871018  1
2003 Grimm D, Zhou S, Nakai H, Thomas CE, Storm TA, Fuess S, Matsushita T, Allen J, Surosky R, Lochrie M, Meuse L, McClelland A, Colosi P, Kay MA. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood. 102: 2412-9. PMID 12791653 DOI: 10.1182/blood-2003-02-0495  1
2003 Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Molecular Therapy : the Journal of the American Society of Gene Therapy. 7: 839-50. PMID 12788658 DOI: 10.1016/S1525-0016(03)00095-9  1
2002 Grimm D. Production methods for gene transfer vectors based on adeno-associated virus serotypes. Methods (San Diego, Calif.). 28: 146-57. PMID 12413413 DOI: 10.1016/S1046-2023(02)00219-0  1
2002 Rohr UP, Kronenwett R, Grimm D, Kleinschmidt J, Haas R. Primary human cells differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression. Journal of Virological Methods. 105: 265-75. PMID 12270659 DOI: 10.1016/S0166-0934(02)00117-9  1
2001 Smith J, Herrero R, Erles K, Grimm D, Muñoz N, Bosch FX, Tafur L, Shah KV, Schlehofer JR. Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia. International Journal of Cancer. Journal International Du Cancer. 94: 520-6. PMID 11745438 DOI: 10.1002/ijc.1496  1
2001 Jiang S, Altmann A, Grimm D, Kleinschmidt JA, Schilling T, Germann C, Haberkorn U. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Therapy. 8: 469-72. PMID 11498767 DOI: 10.1038/sj.cgt.7700327  1
2001 King JA, Dubielzig R, Grimm D, Kleinschmidt JA. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. The Embo Journal. 20: 3282-91. PMID 11406604 DOI: 10.1093/emboj/20.12.3282  1
2000 Kunke D, Grimm D, Denger S, Kreuzer J, Delius H, Komitowski D, Kleinschmidt JA. Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors. Cancer Gene Therapy. 7: 766-77. PMID 10830724 DOI: 10.1038/sj.cgt.7700178  1
1999 Grimm D, Kleinschmidt JA. Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Human Gene Therapy. 10: 2445-50. PMID 10543610 DOI: 10.1089/10430349950016799  1
1999 Grimm D, Kern A, Pawlita M, Ferrari F, Samulski R, Kleinschmidt J. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Therapy. 6: 1322-30. PMID 10455443 DOI: 10.1038/sj.gt.3300946  1
1999 Hörster A, Teichmann B, Hormes R, Grimm D, Kleinschmidt J, Sczakiel G. Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy. Gene Therapy. 6: 1231-8. PMID 10455431 DOI: 10.1038/sj.gt.3300955  1
1999 Hermens WT, ter Brake O, Dijkhuizen PA, Sonnemans MA, Grimm D, Kleinschmidt JA, Verhaagen J. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Human Gene Therapy. 10: 1885-91. PMID 10446928 DOI: 10.1089/10430349950017563  1
1998 Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Human Gene Therapy. 9: 2745-60. PMID 9874273 DOI: 10.1089/hum.1998.9.18-2745  1
1997 Weger S, Wistuba A, Grimm D, Kleinschmidt JA. Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and Rep proteins. Journal of Virology. 71: 8437-47. PMID 9343200  1
1997 Wistuba A, Kern A, Weger S, Grimm D, Kleinschmidt JA. Subcellular compartmentalization of adeno-associated virus type 2 assembly. Journal of Virology. 71: 1341-52. PMID 8995658  1
Show low-probability matches.